Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5583) 5583
Publication (702) 702
Book Review (114) 114
Book Chapter (73) 73
Book / eBook (25) 25
Conference Proceeding (12) 12
Dissertation (3) 3
Newsletter (3) 3
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (3903) 3903
humans (2088) 2088
male (1856) 1856
index medicus (1636) 1636
rats (1560) 1560
cyclic amp - metabolism (1472) 1472
pharmacology & pharmacy (1237) 1237
phosphodiesterase inhibitors - pharmacology (1094) 1094
3',5'-cyclic-amp phosphodiesterases - antagonists & inhibitors (895) 895
mice (868) 868
female (796) 796
neurosciences (764) 764
biochemistry & molecular biology (758) 758
camp (729) 729
cells, cultured (698) 698
cyclic gmp - metabolism (697) 697
in vitro techniques (663) 663
dose-response relationship, drug (657) 657
cyclic amp (643) 643
cell biology (612) 612
phosphodiesterase (578) 578
signal transduction (576) 576
enzyme inhibitors - pharmacology (560) 560
cyclic nucleotide phosphodiesterases, type 4 (506) 506
cyclic-amp (497) 497
phosphorylation (493) 493
physiology (482) 482
rats, sprague-dawley (470) 470
nitric oxide (464) 464
3',5'-cyclic-amp phosphodiesterases - metabolism (413) 413
activation (413) 413
expression (402) 402
calcium - metabolism (397) 397
cyclic amp-dependent protein kinases - metabolism (389) 389
nitric-oxide (384) 384
cgmp (378) 378
signal transduction - drug effects (375) 375
kinetics (366) 366
colforsin - pharmacology (365) 365
proteins (344) 344
cyclic amp - physiology (343) 343
rats, wistar (343) 343
dependent protein-kinase (342) 342
adenylyl cyclases - metabolism (335) 335
rolipram (332) 332
calcium (327) 327
phosphodiesterase inhibitors - therapeutic use (317) 317
analysis (316) 316
3',5'-cyclic-gmp phosphodiesterases - antagonists & inhibitors (314) 314
cells (313) 313
article (304) 304
cyclic gmp (304) 304
signal transduction - physiology (302) 302
1-methyl-3-isobutylxanthine - pharmacology (301) 301
inhibition (298) 298
cell line (292) 292
cyclic nucleotide phosphodiesterases, type 5 (288) 288
physiological aspects (283) 283
time factors (281) 281
cyclic adenylic acid (279) 279
endocrinology & metabolism (271) 271
nitric oxide - metabolism (267) 267
cyclic amp - pharmacology (264) 264
sildenafil citrate (263) 263
kinases (261) 261
research (261) 261
in-vitro (260) 260
cyclic-nucleotide phosphodiesterases (258) 258
cyclic nucleotide phosphodiesterases, type 3 (248) 248
phosphoric diester hydrolases - metabolism (247) 247
receptors (242) 242
structure-activity relationship (240) 240
guinea pigs (238) 238
isoproterenol - pharmacology (236) 236
sildenafil (235) 235
chemistry, medicinal (230) 230
piperazines - pharmacology (221) 221
gene expression (220) 220
rodents (219) 219
cyclic gmp - pharmacology (218) 218
nitric-oxide synthase (217) 217
cyclic amp-dependent protein kinases - antagonists & inhibitors (213) 213
cyclic-nucleotide phosphodiesterase (213) 213
rolipram - pharmacology (212) 212
cyclic-gmp (211) 211
enzymes (210) 210
disease models, animal (208) 208
mice, inbred c57bl (207) 207
adult (206) 206
adenosine (204) 204
cardiac & cardiovascular systems (204) 204
protein kinases (201) 201
rat (200) 200
rabbits (199) 199
receptor (198) 198
brain (197) 197
protein-kinase (194) 194
adenylate-cyclase (193) 193
phosphodiesterase inhibitors (193) 193
isoenzymes - antagonists & inhibitors (191) 191
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (16) 16
UofT at Mississauga - Stacks (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Gerstein Science - Periodical Stacks (1) 1
Online Resources - Online (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Cardiac phosphodiesterases and their modulation for treating heart disease
by Kim, Grace E and Kass, David A
Handbook of Experimental Pharmacology, ISSN 0171-2004, 2017, Volume 243, pp. 249 - 269
An important hallmark of cardiac failure is abnormal second messenger signaling due to impaired synthesis and catabolism of cyclic adenosine 3',5'-... 
Heart failure | Protein kinase A | Myocardium | Cyclic nucleotides | Phosphodiesterases | Protein kinase G | Cyclic Nucleotide Phosphodiesterases, Type 2 - antagonists & inhibitors | 3',5'-Cyclic-AMP Phosphodiesterases - metabolism | Phosphodiesterase Inhibitors - therapeutic use | Heart Diseases - metabolism | Signal Transduction | Humans | Cyclic Nucleotide Phosphodiesterases, Type 2 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 1 - metabolism | Heart Failure - metabolism | Phosphodiesterase 3 Inhibitors - therapeutic use | Cardiomyopathy, Dilated - metabolism | Heart Failure - drug therapy | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Animals | Cardiomyopathy, Dilated - drug therapy | Cyclic GMP - metabolism | Heart Diseases - drug therapy | Phosphodiesterase 5 Inhibitors - therapeutic use | Cyclic Nucleotide Phosphodiesterases, Type 3 - metabolism | Cyclic AMP - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism
Journal Article
Details down arrow
2. Full Text Role of cAMP-Phosphodiesterase 1C Signaling in Regulating Growth Factor Receptor Stability, Vascular Smooth Muscle Cell Growth, Migration, and Neointimal Hyperplasia
by Cai, Yujun and Nagel, David J and Zhou, Qian and Cygnar, Katherine D and Zhao, Haiqing and Li, Faqian and Pi, Xinchun and Knight, Peter A and Yan, Chen
Circulation Research, ISSN 0009-7330, 03/2015, Volume 116, Issue 7, pp. 1120 - 1132
RATIONALE:Neointimal hyperplasia characterized by abnormal accumulation of vascular smooth muscle cells (SMCs) is a hallmark of occlusive disorders such as... 
Smooth muscle cell | Cyclic nucleotide phosphodiesterases, type 1C | Neointima formation | neointima formation | CARDIAC & CARDIOVASCULAR SYSTEMS | smooth muscle cell | TYROSINE PHOSPHORYLATION | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | DEPENDENT PROTEIN-KINASE | cyclic nucleotide phosphodiesterases, type 1C | CORONARY-ARTERY | ELUTING STENTS | CORECEPTOR FUNCTION | MEDIATED ENDOCYTOSIS | MOUSE MODEL | BETA PDGFR-BETA | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | MACROPHAGE DIFFERENTIATION | Humans | Male | Lysosomes - physiology | Cyclic AMP - physiology | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | RNA Interference | Proteolysis | Cell Division | Neointima - enzymology | Models, Animal | Protein Stability | Myocytes, Smooth Muscle - cytology | Cyclic Nucleotide Phosphodiesterases, Type 1 - physiology | Carotid Artery Injuries - pathology | Receptor, Platelet-Derived Growth Factor beta - metabolism | Myocytes, Smooth Muscle - enzymology | Mice, Inbred C57BL | Cells, Cultured | Enzyme Induction | Low Density Lipoprotein Receptor-Related Protein-1 - metabolism | Rats | Muscle, Smooth, Vascular - cytology | Rats, Sprague-Dawley | Endocytosis - physiology | Mice, Knockout | Protein Interaction Mapping | Neointima - physiopathology | Cyclic Nucleotide Phosphodiesterases, Type 1 - deficiency | Animals | Carotid Artery Injuries - enzymology | Signal Transduction - physiology | Mice | Cell Movement | smooth muscle cells | phosphodiesterase | cyclic nucleotide | and neointimal hyperplasia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1
by Humphrey, John M and Movsesian, Matthew and am Ende, Christopher W and Becker, Stacey L and Chappie, Thomas A and Jenkinson, Stephen and Liras, Jennifer L and Liras, Spiros and Orozco, Christine and Pandit, Jayvardhan and Vajdos, Felix F and Vandeput, Fabrice and Yang, Eddie and Menniti, Frank S and Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Journal of Medicinal Chemistry, ISSN 0022-2623, 05/2018, Volume 61, Issue 10, pp. 4635 - 4640
We disclose the discovery and X-ray cocrystal data of potent, selective quinazoline inhibitors of PDE1. Inhibitor (S)-3 readily attains free plasma... 
HEART | ALIGNMENT | CHEMISTRY, MEDICINAL | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Myocardium - enzymology | Humans | Models, Molecular | Phosphodiesterase Inhibitors - pharmacology | Protein Conformation | Molecular Structure | Phosphodiesterase Inhibitors - chemistry | Cyclic AMP - metabolism | Drug Discovery | Quinazolines - chemistry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Phosphodiesterase isoform‐specific expression induced by traumatic brain injury
by Oliva, Anthony A and Kang, Yuan and Furones, Concepcion and Alonso, Ofelia F and Bruno, Olga and Dietrich, W. Dalton and Atkins, Coleen M
Journal of Neurochemistry, ISSN 0022-3042, 12/2012, Volume 123, Issue 6, pp. 1019 - 1029
Traumatic brain injury (TBI) results in significant inflammation which contributes to the evolving pathology. Previously, we have demonstrated that cyclic AMP... 
traumatic brain injury | phosphodiesterase | cAMP | fluid‐percussion | inflammation | isoform | fluid-percussion | FUNCTIONAL RECOVERY | LOCALIZATION | DIFFERENTIAL EXPRESSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | SPLICE VARIANTS | NEUROSCIENCES | PDE4 INHIBITORS | ROLIPRAM | RAT-BRAIN | TNF-ALPHA | CAMP-SPECIFIC PHOSPHODIESTERASES | Cyclic Nucleotide Phosphodiesterases, Type 3 - genetics | Phosphoric Diester Hydrolases - biosynthesis | Male | Cyclic Nucleotide Phosphodiesterases, Type 1 - biosynthesis | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Phosphorylation - genetics | Cyclic Nucleotide Phosphodiesterases, Type 3 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - biosynthesis | Disease Models, Animal | Phosphoric Diester Hydrolases - metabolism | Isoenzymes - genetics | Brain Injuries - enzymology | Rats | Phosphoric Diester Hydrolases - genetics | Brain Injuries - genetics | Brain Injuries - therapy | Cyclic Nucleotide Phosphodiesterases, Type 4 - genetics | Rats, Sprague-Dawley | Cyclic Nucleotide Phosphodiesterases, Type 3 - biosynthesis | Cyclic AMP - antagonists & inhibitors | Animals | Cyclic AMP - biosynthesis | Gene Expression Regulation, Enzymologic - genetics | Isoenzymes - biosynthesis | Cyclic Nucleotide Phosphodiesterases, Type 1 - genetics | Isoenzymes - antagonists & inhibitors | Brain | Neurons | Analysis | Injuries | Neurochemistry | Enzymes | Brain damage | Gene expression | Trauma | Ca super(2+)/calmodulin-dependent phosphodiesterase | Phosphorylation | Traumatic brain injury | Cortex (parietal) | Cyclic AMP | Inflammation | Glia | Western blotting
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Phosphodiesterase 1 regulation is a key mechanism in vascular aging
by Nino, Paula K. Bautista and Durik, Matej and Danser, A. H. Jan and de Vries, Rene and Musterd-Bhaggoe, Usha M and Meima, Marcel E and Kavousi, Maryam and Ghanbari, Mohsen and Hoeijmakers, Jan H and O'Donnell, Christopher J and Franceschini, Nora and Janssen, Ger M. J and De Mey, Jo G. R and Liu, Yiwen and Shanahan, Catherine M and Franco, Oscar H and Dehghan, Abbas and Roks, Anton J. M
Clinical Science, ISSN 0143-5221, 12/2015, Volume 129, Issue 12, pp. 1061 - 1075
Reduced nitric oxide (NO)/cGMP signalling is observed in age-related vascular disease. We hypothesize that this disturbed signalling involves effects of... 
genetic association | phosphodiesterases | blood pressure | aging | vascular disease | Vascular disease | Aging | Blood pressure | Genetic association | Phosphodiesterases | MEDICINE, RESEARCH & EXPERIMENTAL | OXIDATIVE-STRESS | ENDOTHELIAL DYSFUNCTION | ATHEROSCLEROSIS | BLOOD-PRESSURE | ARTERIAL | DISEASE | NITRIC-OXIDE | VINPOCETINE | CONGESTIVE-HEART-FAILURE | ASSOCIATION | Blood Pressure | Endonucleases - deficiency | Endonucleases - genetics | Humans | Hyperplasia | Gene Expression Regulation, Neoplastic | DNA-Binding Proteins - deficiency | Dose-Response Relationship, Drug | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Aging - genetics | Carotid Artery Diseases - pathology | Cellular Senescence | Carotid Arteries - enzymology | Hypertension - enzymology | Hypertension - genetics | Myocytes, Smooth Muscle - drug effects | Phosphodiesterase 5 Inhibitors - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Second Messenger Systems | Muscle, Smooth, Vascular - drug effects | Genetic Predisposition to Disease | Genome-Wide Association Study | Vasodilator Agents - pharmacology | Carotid Intima-Media Thickness | Myocytes, Smooth Muscle - enzymology | Mice, Inbred C57BL | Cells, Cultured | Cyclic Nucleotide Phosphodiesterases, Type 1 - metabolism | DNA-Binding Proteins - genetics | Hypertension - physiopathology | Mice, Knockout | Hydrolysis | Phenotype | Animals | Cyclic GMP - metabolism | Carotid Artery Diseases - enzymology | Carotid Artery Diseases - genetics | Cyclic Nucleotide Phosphodiesterases, Type 5 - genetics | Carotid Arteries - pathology | Polymorphism, Single Nucleotide | Vasodilation - drug effects | In Vitro Techniques | Cyclic Nucleotide Phosphodiesterases, Type 1 - genetics | Muscle, Smooth, Vascular - enzymology | Aging - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases
by Li, Peng and Zheng, Hailin and Zhao, Jun and Zhang, Lei and Yao, Wei and Zhu, Hongwen and Beard, J. David and Ida, Koh and Lane, Weston and Snell, Gyorgy and Sogabe, Satoshi and Heyser, Charles J and Snyder, Gretchen L and Hendrick, Joseph P and Vanover, Kimberly E and Davis, Robert E and Wennogle, Lawrence P
Journal of Medicinal Chemistry, ISSN 0022-2623, 02/2016, Volume 59, Issue 3, pp. 1149 - 1164
A diverse set of 3-aminopyrazolo­[3,4-d]­pyrimidinones was designed and synthesized. The structure–activity relationships of these polycyclic compounds as... 
CHEMISTRY, MEDICINAL | MECHANISM | PDE1 | INFORMATION | SCHIZOPHRENIA | RECEPTOR | MOLECULAR-CLONING | LIGAND | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE | DEFICITS | PROGRAM | Humans | Microsomes, Liver - metabolism | Male | Mental Disorders - complications | Structure-Activity Relationship | Neurodegenerative Diseases - drug therapy | Dose-Response Relationship, Drug | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Mental Disorders - enzymology | Cattle | Molecular Structure | Phosphodiesterase Inhibitors - chemistry | Cognition Disorders - enzymology | Cyclic Nucleotide Phosphodiesterases, Type 1 - metabolism | Models, Molecular | Phosphodiesterase Inhibitors - pharmacology | Rats | Cognition Disorders - drug therapy | Microsomes, Liver - chemistry | Drug Discovery | Neurodegenerative Diseases - complications | Rats, Sprague-Dawley | Cognition Disorders - complications | Animals | Phosphodiesterase Inhibitors - metabolism | Mental Disorders - drug therapy | Neurodegenerative Diseases - enzymology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Exploring pyrazolo[3,4-d]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: a predictive approach combining comparative validated multiple molecular modelling techniques
by Amin, Sk. Abdul and Bhargava, Sonam and Adhikari, Nilanjan and Gayen, Shovanlal and Jha, Tarun
Journal of Biomolecular Structure and Dynamics, ISSN 0739-1102, 02/2018, Volume 36, Issue 3, pp. 590 - 608
Phosphodiesterase 1 (PDE1) is a potential target for a number of neurodegenerative disorders such as Schizophrenia, Parkinson's and Alzheimer's diseases. A... 
phosphodiesterase 1 | pyrazolo[3,4-d]pyrimidine | classification-QSAR | molecular docking | Open3DQSAR | pharmacophore mapping | molecular modelling | regression-QSAR | machine learning | PROTEIN | BIOCHEMISTRY & MOLECULAR BIOLOGY | COGNITIVE IMPAIRMENT | IDENTIFICATION | DISCOVERY | POTENT | BIOPHYSICS | QSAR | CLONING | 4-d]pyrimidine | PHARMACOPHORE | DERIVATIVES | pyrazolo | INTERACTION MECHANISM | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Pyrazoles - chemistry | Cyclic Nucleotide Phosphodiesterases, Type 1 - chemistry | Enzyme Inhibitors - chemistry | Humans | Bayes Theorem | Models, Molecular | Molecular Docking Simulation | Molecular Structure | Pyrimidines - chemistry | Pyrimidinones - chemistry | Quantitative Structure-Activity Relationship
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Anti‐proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1
by Abusnina, Abdurazzag and Keravis, Thérèse and Yougbaré, Issaka and Bronner, Christian and Lugnier, Claire
Molecular Nutrition & Food Research, ISSN 1613-4125, 11/2011, Volume 55, Issue 11, pp. 1677 - 1689
Scope: Curcumin inhibits proliferation of many cancer cells. Cyclic nucleotide phosphodiesterases (PDEs), by hydrolyzing intracellular cyclic... 
DNMT1 | Rolipram | Nimodipine | cAMP/cGMP | Cancer | CAMP/cGMP | CANCER-CELLS | APOPTOSIS | HEMI-METHYLATED DNA | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | FOOD SCIENCE & TECHNOLOGY | DOWN-REGULATION | VASCULAR SMOOTH-MUSCLE | ARREST | SRA DOMAIN | ENDOTHELIAL-CELLS | GENE-EXPRESSION | Neoplasm Proteins - antagonists & inhibitors | Cyclin-Dependent Kinase Inhibitor Proteins - metabolism | Molecular Targeted Therapy | Neoplasm Proteins - metabolism | RNA, Messenger - metabolism | DNA (Cytosine-5-)-Methyltransferases - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Isoenzymes - metabolism | Gene Expression Regulation, Neoplastic - drug effects | Melanoma - metabolism | Recombinant Proteins - metabolism | Cell Survival - drug effects | DNA (Cytosine-5-)-Methyltransferase 1 | Isoenzymes - genetics | Curcumin - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 1 - metabolism | Phosphodiesterase Inhibitors - pharmacology | Nuclear Proteins - metabolism | Animals | Cyclic GMP - metabolism | Melanoma - drug therapy | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Antineoplastic Agents, Phytogenic - pharmacology | Cell Cycle - drug effects | Cyclic Nucleotide Phosphodiesterases, Type 1 - genetics | Isoenzymes - antagonists & inhibitors | Cell proliferation | Ca super(2+)/calmodulin-dependent phosphodiesterase | 3',5'-Cyclic-nucleotide phosphodiesterase | DNMT1 protein | Melanoma | Cyclic AMP | epigenetics | Signal transduction | Cyclic GMP | Cyclin A | Cell cycle | Cyclin-dependent kinase inhibitor p27 | DNA methyltransferase | Curcumin | phosphodiesterase | cyclin-dependent kinase inhibitors | Food | Life Sciences | Cellular Biology | Biochemistry, Molecular Biology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Novel selective PDE type 1 inhibitors cause vasodilatation and lower blood pressure in rats
by Laursen, Morten and Beck, Lilliana and Kehler, Jan and Christoffersen, Claus Tornby and Bundgaard, Christoffer and Mogensen, Susie and Mow, Tomas Joachim and Pinilla, Estéfano and Knudsen, Jakob Schöllhammer and Hedegaard, Elise Røge and Grunnet, Morten and Simonsen, Ulf
British Journal of Pharmacology, ISSN 0007-1188, 08/2017, Volume 174, Issue 15, pp. 2563 - 2575
Background and Purpose The PDE enzymes (PDE1–11) hydrolyse and thus inactivate cyclic nucleotides and are important in the regulation of the cardiovascular... 
MUSCLE-CELL GROWTH | PUBLICATION | SILDENAFIL | PULMONARY-HYPERTENSION | CONCISE GUIDE | PHARMACOLOGY | RELAXATION | PHARMACOLOGY & PHARMACY | MESENTERIC-ARTERY | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE | CAMP | Dose-Response Relationship, Drug | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Animals | Cyclic Nucleotide Phosphodiesterases, Type 1 - metabolism | Phosphodiesterase Inhibitors - pharmacology | Rats | Male | Blood Pressure - drug effects | Molecular Structure | Structure-Activity Relationship | Phosphodiesterase Inhibitors - chemistry | Vasodilation - drug effects | Hypertension | Heart | Nucleotides | Hemodynamics | Vasodilators | Enzyme activity | Guanylate cyclase | Dosage | Arteries | Vasodilation | Adenylate cyclase | Isometric | Rodents | Phenylephrine | Aorta | Blood pressure | Cardiovascular system | Enzymes | Transducers | Vasoconstriction | Endothelium | Polymerase chain reaction | Ca2+/calmodulin-dependent phosphodiesterase | Heart rate | Inhibitors | Cyclic nucleotides | Nitric oxide | Veins & arteries | Research Papers | Research Paper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text PDE1A inhibition elicits cGMP‐dependent relaxation of rat mesenteric arteries
by Khammy, Makhala Michell and Dalsgaard, Thomas and Larsen, Peter Hjørringgaard and Christoffersen, Claus Tornby and Clausen, Dorte and Rasmussen, Lars Kyhn and Folkersen, Lasse and Grunnet, Morten and Kehler, Jan and Aalkjær, Christian and Nielsen, Jacob
British Journal of Pharmacology, ISSN 0007-1188, 11/2017, Volume 174, Issue 22, pp. 4186 - 4198
Background and Purpose PDE1, a subfamily of cyclic nucleotide PDEs consisting of three isoforms, PDE1A, PDE1B and PDE1C, has been implicated in the regulation... 
CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | ENDOTHELIUM | PROTEIN-KINASE | PHARMACOLOGY | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | UP-REGULATION | CELL GROWTH | VASCULAR SMOOTH-MUSCLE | BLOOD-PRESSURE | GUANYLATE-CYCLASE | Mesenteric Arteries - physiology | Cyclic GMP - physiology | Rats, Wistar | Isoenzymes - genetics | Myocytes, Smooth Muscle - enzymology | Myocytes, Smooth Muscle - physiology | Phosphodiesterase Inhibitors - pharmacology | Male | Mesenteric Arteries - drug effects | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Animals | Vasodilation - drug effects | Myocytes, Smooth Muscle - drug effects | Cyclic Nucleotide Phosphodiesterases, Type 1 - genetics | Mesenteric Arteries - enzymology | Cyclic Nucleotide Phosphodiesterases, Type 1 - physiology | Isoenzymes - antagonists & inhibitors | Isoenzymes - physiology | RNA | Arteries | Protein kinase A | Ca2 /calmodulin-dependent phosphodiesterase | Muscles | Smooth muscle | Nucleotides | Gene expression | Muscle contraction | Nitric-oxide synthase | NG-Nitroarginine methyl ester | Inhibitors | Cyclic GMP | Nitric oxide | Rodents | Isoforms | Physiology | Inhibition | Localization | Research Papers | Research Paper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats
by Snyder, Gretchen L and Prickaerts, Jos and Wadenberg, Marie-Louise and Zhang, Lei and Zheng, Hailin and Yao, Wei and Akkerman, Sven and Zhu, Hongwen and Henick, Joseph P and Vanover, Kimberly E and Davis, Robert and Li, Peng and Mates, Sharon and Wennogle, Lawrence P and Linnéuniversitetet and Institutionen för kemi och biomedicin (KOB) and Fakulteten för Hälso- och livsvetenskap (FHL)
Psychopharmacology, ISSN 0033-3158, 09/2016, Volume 233, Issue 17, pp. 3113 - 3124
Therapeutic agents for memory enhancement in psychiatric disorders, such as schizophrenia, are urgently needed.The aim of this study is to characterize the... 
Phosphodiesterase-1 | Cyclic AMP | Novel object recognition | Cyclic GMP | Memory | Conditioned avoidance response | Neurosciences | Biomedicine | Pharmacology/Toxicology | Psychiatry | LONG-TERM-MEMORY | OBJECT RECOGNITION MEMORY | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | PSYCHIATRY | COGNITIVE IMPAIRMENT | TANDEM MASS-SPECTROMETRY | NEUROSCIENCES | ANTIPSYCHOTIC-DRUGS | PHARMACOLOGY & PHARMACY | MOLECULAR-CLONING | DOPAMINE D-1 | CONDITIONED AVOIDANCE-RESPONSE | WORKING-MEMORY | Memory - drug effects | Risperidone - pharmacology | Phosphodiesterase Inhibitors - pharmacology | Rats | Schizophrenia | Male | Schizophrenic Psychology | Heterocyclic Compounds, 4 or More Rings - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Animals | Drug Interactions | Recognition (Psychology) - drug effects | Exploratory Behavior - drug effects | Antipsychotic Agents - pharmacology | Nootropic Agents - pharmacology | Enzyme inhibitors | Patient outcomes | Dosage and administration | Phosphodiesterases | Health aspects | Enzymes | Neuropsychology | Rodents | Animal memory | Psychopharmacology | Original Investigation | Pharmaceutical Sciences | Basic Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Farmaceutiska vetenskaper | Pharmacology | Farmakologi | Medicinska och farmaceutiska grundvetenskaper | Farmakologi och toxikologi | Pharmacology and Toxicology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text β-Adrenergic cAMP Signals Are Predominantly Regulated by Phosphodiesterase Type 4 in Cultured Adult Rat Aortic Smooth Muscle Cells
by Zhai, Kui and Hubert, Fabien and Nicolas, Valérie and Ji, Guangju and Fischmeister, Rodolphe and Leblais, Véronique
PLoS ONE, ISSN 1932-6203, 10/2012, Volume 7, Issue 10, p. e47826
Background: We investigated the role of cyclic nucleotide phosphodiesterases (PDEs) in the spatiotemporal control of intracellular cAMP concentrations in rat... 
SELECTIVE INHIBITOR | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | ADENYLYL-CYCLASE | MULTIDISCIPLINARY SCIENCES | CARDIAC MYOCYTES | NITRIC-OXIDE | CGMP | DEPENDENT PROTEIN-KINASE | PROLIFERATION | CARDIOVASCULAR TISSUES | EXPRESSION | Aorta - metabolism | Adrenergic beta-Antagonists - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Time Factors | Fluorescence Resonance Energy Transfer | Cyclic Nucleotide Phosphodiesterases, Type 3 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Myocytes, Smooth Muscle - drug effects | Cyclic AMP - metabolism | Myocytes, Smooth Muscle - cytology | Cell Membrane - drug effects | Muscle, Smooth, Vascular - drug effects | Myocytes, Smooth Muscle - enzymology | Aorta - drug effects | Cyclic Nucleotide Phosphodiesterases, Type 7 - metabolism | Adrenergic beta-Agonists - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 1 - metabolism | Phosphodiesterase Inhibitors - pharmacology | Rats | Muscle, Smooth, Vascular - cytology | Cell Membrane - enzymology | Animals | Signal Transduction - drug effects | Isoproterenol - pharmacology | Signal Transduction - physiology | Aorta - cytology | Primary Cell Culture | Muscle, Smooth, Vascular - enzymology | Laboratories | Fluorescence | Smooth muscle | Antagonists | Isoproterenol | Kinases | Recovery | Experiments | Proteins | Dynamic control | Rodents | Aorta | Physiology | Inhibition | Fluorescence resonance energy transfer | Localization | Phosphodiesterase | 3',5'-Cyclic-nucleotide phosphodiesterase | Muscles | Cyclic AMP | Biophysics | Gene expression | Endothelium | Studies | Inhibitors | Coronary vessels | Nitric oxide | Adrenergic receptors | Kinetics | Intracellular | Energy transfer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Pleiotropic roles of Ca+2/calmodulin-dependent pathways in regulating cadmium-induced toxicity in human osteoblast-like cell lines
by Ha, Thao T and Burwell, Shalimar T and Goodwin, Matthew L and Noeker, Jacob A and Heggland, Sara J
Toxicology Letters, ISSN 0378-4274, 10/2016, Volume 260, pp. 18 - 27
The heavy metal cadmium is a widespread environmental contaminant that has gained public attention due to the global increase in cadmium-containing electronic... 
Osteoblast | Cadmium | Calmodulin | Apoptosis | ACTIVATED PROTEIN-KINASE | INDUCED APOPTOSIS | CYCLE ARREST | ERK ACTIVATION | E-WASTE | IN-VITRO | GENE-EXPRESSION | TOXICOLOGY | INHIBITOR | EXPOSURE | Calmodulin - agonists | Apoptosis - drug effects | Cyclic Nucleotide Phosphodiesterases, Type 1 - chemistry | Humans | Cyclic Nucleotide Phosphodiesterases, Type 1 - antagonists & inhibitors | Environmental Pollutants - antagonists & inhibitors | Environmental Pollutants - toxicity | Cadmium - agonists | Calcium-Calmodulin-Dependent Protein Kinase Type 2 - metabolism | Biomarkers - metabolism | Calmodulin - metabolism | Cadmium - toxicity | Osteoblasts - enzymology | Osteoblasts - drug effects | Cyclic Nucleotide Phosphodiesterases, Type 1 - metabolism | Phosphodiesterase Inhibitors - pharmacology | Lethal Dose 50 | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Calcium-Calmodulin-Dependent Protein Kinase Type 2 - antagonists & inhibitors | Calcium-Calmodulin-Dependent Protein Kinase Kinase - chemistry | Calcium-Calmodulin-Dependent Protein Kinase Type 2 - chemistry | MAP Kinase Signaling System - drug effects | Naphthalimides - pharmacology | Calcium Signaling - drug effects | Calcium-Calmodulin-Dependent Protein Kinase Kinase - antagonists & inhibitors | Calcium-Calmodulin-Dependent Protein Kinase Kinase - metabolism | Cell Line, Tumor | Benzimidazoles - pharmacology | Protein Kinase Inhibitors - pharmacology | Osteoblasts - metabolism | Benzylamines - pharmacology | Calmodulin - antagonists & inhibitors | Cadmium - chemistry | Environmental Pollutants - agonists | Index Medicus | Biomedical materials | Inhibitors | Pathways | Toxicity | Activation | Kinases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights